Definitive Contract 75A50123C00067
Award Date
9/21/23
Potential Completion Date
8/31/27
Potential Value
$20M
Awardee
Bioaegis Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Morristown, NJ 07960, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
100
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Bioaegis Therapeutics Inc. was awarded a $749,000 firm fixed price definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop a safe and effective therapeutic to mitigate severe outcomes including mortality in patients with severe infection or sepsis of any etiology. This award was made under Special Instructions 019 to the department's Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought host-directed...
This $135,212,671.14 federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Gigagen Inc., a for-profit foreign-owned company, for the development of a next-generation recombinant polyclonal antibody discovery platform to produce medical countermeasures. The contract was awarded under BARDA's (Biomedical Advanced Research and Development Authority) Broad Agency...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Pattern Bioscience, Inc., a biotechnology company, to develop a rapid pathogen identification and antimicrobial susceptibility testing platform. The contract, valued at $40,937,536.73, is for the verification, clinical evaluation, and U.S. Food and Drug Administration (FDA) clearance of this culture-free, phenotypic diagnostic platform. The contract is a...
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>
<p>This is a $745,507.23 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Swaza Inc., a minority-owned, woman-owned small business, for research and development on the development of a breakthrough nanofluid breathing aid for the treatment of acute respiratory distress. The contract has a period of performance through June 28, 2025 and was awarded on June 29, 2023 with no set-aside designation.</p>
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $119,642,445 Cost Plus Fixed Fee contract to Synedgen, Inc., a for-profit organization, to advance the development of PAAG17G (drug product: MIIST305), a once-daily, orally administered, gut-restricted drug to reduce mortality and morbidity arising from acute exposure to ionizing radiation, specifically gastrointestinal (GI) injury (GI-AR). This contract was not set aside...
This federal contract award is an Other Transaction Agreement between Global Life Sciences Solutions USA LLC and the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency. The $72,104,359.91 cost-sharing agreement is focused on expanding capacity for COVID-19 response and supporting public health emergencies, with a completion date of December 31, 2038. Global Life Sciences Solutions USA LLC, a for-profit limited liability company and wholly owned subsidiary...
This is a $37,000 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Protein Sciences Corp, a for-profit manufacturer, to provide purified recombinant proteins. The contract has no set-aside designation. Protein Sciences Corp has received multiple federal contract awards from HHS's Office of the Assistant Secretary for Preparedness and Response...